We seek to exploit an investment edge that is both analytical and behavioural in nature. Being long term in outlook, concentrated, and benchmark agnostic allows us to ask the right questions. Our cash-flow focus, awareness of time and resource constraints, and strong emphasis on investor culture allows us to answer analytical questions in a more robust, and consistent fashion.
Our approach is benchmark agnostic in terms of stock selection, which allows us to invest without restriction and take meaningful positions in companies on a forward-looking fundamental basis (rather than be beholden to the skews of global equity indices). Instead, we choose what we consider to be the very best businesses regardless of sector classification or geographic listing.
We actively seek to minimise downside risk, typically reflected in an attractive capture ratio – aiming to match the market on the way up, but significantly outperform it on the way down.
For further information on the risks and risk profiles of our funds, please refer to the relevant KIID and Prospectus.
The value of an investment and any income from it can go down as well as up and can fluctuate in response to changes in currency and exchange rates. Investors may not get back the original amount invested.
Global equities in focus
We need to talk about capture ratios
Giles Parkinson explains why a simple, but underused, metric can help investors judge portfolio manager skill.
Risk: Adjusting returns
Thinking about risk as losing money and the trade-offs involved in assessing risk and return.
Patient conviction: Beyond ‘active share’
Managing high active share portfolios with low turnover fosters an analytical edge.
Psychological safety: Culture as a competitive advantage
Being safely wrong early and bravely right in the long term.
Discounted cash flow: Better to be roughly right than precisely wrong
The importance and greater relevance of looking at cash flows rather than earnings.
Conscious consciences: Active managers as the new activists
Is passive investment responsible? Put another way, are long-term institutional investors the new activists?
Diversity of thought and the collective intelligence challenge
Exploring neurodiversity, and why it matters when investing.
Growth, returns and cash: Are management incentives aligned?
What exactly does capital allocation mean, why is it so important, and how do we analyse it?
Out of style: Don’t restrict your investment universe
It is important to source ideas from the broadest possible opportunity set without style factors or other constraints.
The behavioural investment edge
Exploring the durability and replicability of investing edges.
Read more about the fund
Explore our equities range
Climate Transition Equities
A range of strategies investing in companies that can play a major role in the transition to a low-carbon world.
Our range of strategies is underpinned by a robust process designed to meet clients' objectives across capital growth and income.
Global emerging market equities
A range of strategies that offer investors specialist exposure to a rapidly growing asset class, with portfolios targeting income and smaller companies.
Covering both continental and pan-European regions, our range of equity funds focus on identifying companies with improving fundamentals.
Social Transition Global Equity Fund
An equity strategy seeking positive social outcomes while delivering long term capital growth.
Natural Capital Transition Global Equity Fund
An equity strategy seeking positive environmental outcomes while delivering long-term capital growth.
Where the wild things are: Why investors should care about natural capital
14 Dec 2021
Finance must wake up to the risks associated with biodiversity loss and the opportunities that arise from nature-friendly solutions, argue Eugenie Mathieu, Julie Zhuang and Jonathan Toub.
The future of pharma: Increased returns or the age of biotech?
8 Dec 2021
After decades of low returns on research and development (R&D), the healthcare sector is producing a slew of innovations, from drugs to diagnostics. But with many coming from new entrants, will big pharmaceutical companies manage to keep up with the times?
The long decline: Why trend economic growth is set to go on falling
12 Nov 2021
Trend rates of economic growth, which have been on the decline for decades in the world’s leading economies, look set to fall further. That will have big implications for governments, companies, households and investors, argues Stewart Robertson.
Regulatory shifts in China: A new fork in the road?
12 Oct 2021
Investors in China should view recent interventions by the government in the context of its history and longer-term strategic ambitions, argues Amy Kam.
The AIQ Podcast: China's tech crackdown
21 Sep 2021
China’s regulators are taking swift, radical action against tech companies they consider to be too big and powerful. How should foreign investors respond?
The taming of the few
27 Aug 2021
Despite accusations Big Tech companies are too powerful, their stranglehold across sectors will be hard to loosen. However, while investors need to keep a watchful eye on developments, Big Tech’s stranglehold on numerous economic sectors will be hard to loosen.
Are bond investors too complacent about inflation?
11 Aug 2021
US Treasury yields have fallen appreciably in recent weeks, seemingly dismissing the threat of rising consumer prices. Some investors could be in for a nasty surprise if inflation proves more intransigent than anticipated, argue Michael Grady and Katarina Cohrs.
Investors should confront the dark side of tech
9 Jul 2021
Technology firms are often favoured by ESG funds because of their ostensibly clean, asset-light business models. But investors need to look deeper and challenge unethical and unsustainable practices across the industry, argue Louise Piffaut and Charles Devereux.
China’s Big Tech crackdown
5 Jul 2021
Like Washington and Brussels, Beijing is worried about the growing power of large technology companies. But China’s regulators are taking swifter, more radical action than their peers in the West.
The Anti-Social Network
2 Jul 2021
Facebook, Twitter and other platforms are drawing criticism for their failure to tackle hate content. But will the hit to their reputation do any lasting commercial damage?
The taming of the few
1 Jul 2021
Regulatory authorities around the world are targeting the big US tech giants. However, while investors need to keep a watchful eye on developments, Big Tech’s stranglehold and influence on numerous economic sectors will be hard to loosen.
Is there now ‘value’ in value investing?
2 Jun 2021
Value or growth? It is an age-old debate and, as Giles Parkinson argues, a slightly irrelevant one given the changing makeup of the economy and the gentle decoupling of intrinsic value from financial statements.
Green is not always clean: Rising tide of greenwash brings risks for investors
19 May 2021
Some companies have long sought to mislead the public about their commitments to sustainability, but greenwashing has become more widespread and sophisticated in recent years. Now regulators and investors are fighting back.
How COVID-19 is accelerating the use of new technologies in construction and manufacturing
14 May 2021
During the pandemic, companies have stepped up investments in technology to communicate remotely with customers and keep their businesses running. As well as boosting efficiency and profitability, it also creating investment opportunities in previously overlooked areas.
Flipside: Not all externalities are negative
4 May 2021
ESG factors have long been viewed as risk factors to manage. Giles Parkinson explores the flipside of this proposition, contending that positive externalities are an under-leveraged investment opportunity.
What does the data say? Vaccines, illiquidity and managers called Dave
26 Mar 2021
In the first of a new monthly series, we take a visual approach to illustrate topical data themes in economies, markets and beyond. This month we look at the correlation between stock market performance and vaccinations, the illiquidity premium in real assets, and whether there are still more men called Dave running funds than female managers.